Table 1 |
||||||
|
Agonist Pharmacology in HEK and L-cells. |
||||||
|
GlyR α2 |
GlyR α2β |
|||||
|
System |
log EC50 |
EC50 (mM) |
Efficacya |
log EC50 |
EC50 (mM) |
Efficacy |
|
|
||||||
|
Glycine |
||||||
|
HEK |
-3.67 ± 0.15 |
0.22 |
-- |
-3.55 ± 0.06 |
0.28 |
-- |
|
L-cells |
-3.36 ± 0.05 |
0.43 |
-- |
-3.17 ± 0.04 |
0.67 |
-- |
|
β-Alanine |
||||||
|
HEK |
-3.12 ± 0.05 |
0.76 |
0.80 ± 0.06 |
-3.24 ± 0.03 |
0.57 |
0.55 ± 0.07 |
|
L-cells |
-2.71 ± 0.08b |
1.93 |
0.39 ± 0.08 |
-2.59 ± 0.13 |
2.59 |
0.25 ± 0.05 |
|
Taurine |
||||||
|
HEK |
-3.13 ± 0.12 |
0.74 |
0.48 ± 0.12 |
-2.67 ± 0.12 |
2.20 |
0.32 ± 0.05 |
|
L-cells |
≥-3.00 ± 0.11c |
1.00 |
0.06 ± 0.01 |
≥-2.97 ± 0.20c |
1.10 |
0.05 ± 0.01 |
|
|
||||||
|
a – efficacy relative to maximal glycine response b – p < 0.0001 for system but not subunit using two-way ANOVA c – estimate due to low efficacy |
||||||
|
Farroni and McCool BMC Pharmacology 2004 4:16 doi:10.1186/1471-2210-4-16 |
||||||
